Back in April, the AIM-quoted group revealed it had found a different series of new mechanism antibiotics for the sexually transmitted infection which is notoriously difficult to treat because of its high resistances rates.
Initial research has suggested that these new compounds have the characteristics to kill the bacteria, including the resistant strains.
“Gonorrhoea poses an urgent threat as the world approaches an era of untreatable disease due to increasing resistance against the last recommended treatment option," said Summit’s president of R&D, David Roblin.
“Having two novel approaches with the potential to combat gonorrhoea means Summit has an opportunity to meaningfully contribute to the fight against this significant worldwide health threat.”
Both series of compounds were identified using Summit’s Discuva platform – a genetics-based technology used for the discovery and development of new antibiotics against infections generally associated with antibiotic resistance.
Roblin added: “We believe our Discuva Platform has the potential to radically change antibiotic drug discovery and development.”
Currently there is only on treatment option for gonorrhoea recommended by the US Centres for Disease Control, although the bacteria’s resistance is rising all the time.
The World Health Organisation estimates there are 78mln new cases of the infection around the world every year.
Summit shares edged 0.8% to 194p.